Ireland · Delayed Price · Currency is EUR Uniphar Earnings Call Transcripts
Fiscal Year 2025
-
Strong organic growth across all divisions drove EBITDA up 6% and EPS up 21% year-over-year, supported by strategic investments in infrastructure and technology. The group remains confident in achieving its EUR 200 million EBITDA target by 2028, with robust performance in pharma, medtech, and retail.
-
Strong H1 2025 results with 8% organic gross profit growth and 21% EPS increase, driven by all divisions. Strategic investments in infrastructure and technology are expected to support medium-term EBITDA growth, with a €200m target by 2028.
Fiscal Year 2024
-
Strong 2024 results featured 9.6% gross profit growth, 12% EPS increase, and robust performance across all divisions. Strategic investments and a €35 million share buyback support a €200 million EBITDA target by 2028, with 80% expected from organic growth.
-
Revenue and gross profit both grew 10% year-over-year, with Pharma leading at 21% gross profit growth. EBITDA rose 6%, leverage improved, and strong organic growth was achieved across all divisions. The group remains confident in its ambitious €200m EBITDA target.